AI assistant
Anteris Technologies Global Corp. — Share Issue/Capital Change 2015
Nov 25, 2015
33869_rns_2015-11-25_884fba06-f3e8-46b6-bab7-038f3818f68c.pdf
Share Issue/Capital Change
Open in viewerOpens in your device viewer
==> picture [226 x 82] intentionally omitted <==
ADMEDUS LIMITED ABN 35 088 221 078
REGISTERED OFFICE: 26 Harris Road Malaga Western Australia 6090
Corporate Enquiries: T +61 (0)8 6240 6100 F +61 (0)8 9266 0199
ASX RELEASE
E [email protected] www.admedus.com
NOTICES PROVIDING DETAILS OF SHAREHOLDINGS PRE AND POST CONSOLIDATION
Brisbane, Australia 26[th] November, 2015
Pursuant to ASX Listing Rule 3.17.1, Admedus Limited (ASX: AHZ) is pleased to announce that letters have been dispatched to shareholders today providing details of their shareholdings pre and post consolidation. A copy of the letter sent to shareholders is attached.
Follow us: Twitter: @Admedus Facebook: www.facebook.com/pages/Admedus
For more information, please contact:
Dr Julian Chick | Chief Operating Officer | Admedus Limited Tel: +61 (0)8 9266 0100
Media :
Shevaun Cooper | PR Manager | Admedus Limited Tel: +61 (0) 417 985 599 | Email: [email protected]
About Admedus Limited
Admedus (ASX: AHZ) is a specialist healthcare company. Our focus is on investing in and developing next generation technologies with world class partners, acquiring strategic assets to grow product and service offerings and expanding revenues from our existing, profitable medical sales and distribution business. The company has assets from research & development through clinical development as well as sales, marketing and distribution.
Admedus has commercialised its innovative tissue engineering technology for regenerative medicine in four continents. We also have a major interest in developing the next generation of vaccines with a Brisbane-based research group led by Professor Ian Frazer. The vaccine programmes target disease with significant global potential, such as Herpes and Human Papillomavirus.
Further information on the company can be found on www.admedus.com
==> picture [231 x 85] intentionally omitted <==
Admedus Ltd ABN 35 088 221 078
==> picture [30 x 152] intentionally omitted <==
==> picture [187 x 20] intentionally omitted <==
AHZ SHAREHOLDER NAME SHAREHOLDER ADDRESS
Update your information:
Online:
==> picture [15 x 15] intentionally omitted <==
www.investorcentre.com/contact By Mail: Computershare Investor Services Pty Limited GPO Box 2975 Melbourne Victoria 3001 Australia
==> picture [16 x 13] intentionally omitted <==
Enquiries: (within Australia) 1300 850 505 (international) +61 3 9415 4000
Holder Identification Number (HIN) Securities Sub-Register CHESS PRE CONSOLIDATION POST CONSOLIDATION SHAREHOLDING SHAREHOLDING 400000 40000
26 November 2015
[For your security keep your SRN/HIN confidential]
Dear Shareholder,
At the Annual General Meeting held on 13 November 2015, shareholders approved the resolution authorising a consolidation of the Company's Share Capital on a basis of 1 new share for every 10 shares held. Any resulting fractions of a share have been rounded up to the nearest whole number of shares.
Details of your Shareholding on a pre-consolidation and post consolidation basis are set out above.
If you have any queries please contact Computershare Investor Services Pty Limited on 1300 850 505 (within Australia) or 61 3 9415 4000 (outside Australia).
If you are a broker sponsored holder, you will also be forwarded a statement by the ASX after the end of the month.
Yours faithfully
Stephen Mann CFO/Company Secretary
207564_Live_Samples/000007/000007/i